Current Report Filing (8-k)
October 07 2019 - 8:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) October 7, 2019
Citius
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
11
Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code (908) 967-6677
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
CTXR
|
|
Nasdaq
|
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
October 7, 2019, we issued a press release announcing that our Phase 3 clinical trial for Mino-Lok had reached the first interim
analysis milestone, triggering the data cutoff for futility analysis. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference herein.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
CITIUS
PHARMACEUTICALS, INC.
|
|
|
|
Date:
|
October
7, 2019
|
|
/s/
Myron Holubiak
|
|
|
Myron
Holubiak
|
|
|
President
and Chief Executive Officer
|
2
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Sep 2023 to Sep 2024